---
schema_version: "secwatch.filing_event.v1"
accession: "0001380106-21-000008"
form_type: "8-K"
ticker: "RPID"
cik: "0001380106"
company_name: "RAPID MICRO BIOSYSTEMS, INC."
filed_at: "2021-11-12T23:59:59+00:00"
generated_at: "2026-06-28T09:02:29.729411+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Rapid Micro Biosystems Q3 commercial revenue $6.3M (+27%); reaffirms FY21 outlook

## Summary
- Commercial revenue $6.3M (+27% YoY); recurring commercial revenue $2.2M (+154% YoY).
- Net loss of $25.0M includes $8.2M warrant fair-value adjustment and $3.1M debt-repayment charge.
- Cash $220M, no debt; repaid $28.7M term debt in September using IPO proceeds.
- Placed 10 Growth Direct systems and completed validation of 5 customer systems in Q3.
- Reaffirms FY2021 commercial revenue outlook of at least $24M, representing ≥70% YoY growth.

## SEC filing metadata
- accession: 0001380106-21-000008
- form_type: 8-K
- ticker: RPID
- cik: 0001380106
- company_name: RAPID MICRO BIOSYSTEMS, INC.
- filed_at: 2021-11-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1380106/000138010621000008/0001380106-21-000008-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1380106/000138010621000008/rpid-20211111x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001380106-21-000008
- JSON: https://secwatch.observer/filing/0001380106-21-000008.json
- Plain text: https://secwatch.observer/filing/0001380106-21-000008.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.